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Pathological stage seems to be the major determinant of postoperative prognosis of solid tumors, but additional prognostic
determinants need to be better investigated. The most important tumor marker for colorectal cancer (CRC) is the cell-surface
antigen, Carcinoembryonic Antigen (CEA), and its assessment is considered a valuable index of circulating tumor cells (CTCs). In
this paper, CEACAM3 evaluation was applied given its great specificity in the CRC. Whole blood from the basilic vein of 38 CRC
patients was collected before and at various time intervals after the curative resection. Also, from 20 of them, we have obtained
two additional intraoperative samples. CEACAM3 expression was evaluated in all the samples by RT-PCR. CEACAM3 duct values
showed a decreasing trend from preoperative through early and later postoperative to 6th-month samples (𝑝 < 0.001).The average
values of CEACAM3 were related to the cancer size (T stage) (𝑝 = 0.034) and WHO stage (𝑝 = 0.035). A significant effect of the
baseline value of CEACAM3 dCt on the temporal trend has been observed (𝑝 < 0.001). In this study, we have demonstrated the
CEACAM3 specificity and a perioperative trend of CTCs which is coherent with the clinical/pathological considerations and with
previous experimental findings in different cancer types.
1. Introduction
Pathological stage seems to be themajor determinant of post-
operative prognosis of solid tumors. This is true also for
colorectal cancer (CRC) which is the second most com-
mon cause of cancer-related death in Europe and United
States [1, 2]. However, within the same pathological stage,
different patients may have very different disease outcomes.
This remark supports the relevance of additional prognostic
determinants, which are possibly linked either to the host
responsiveness or to the tumor aggressiveness [3, 4]. Among
the latter, in addition to vascular or perineural invasion and/
or tumor differentiation andmolecular characteristics, tumor
markers such as the amount of circulating cancer cells/
micrometastases (CTCs) may be relevant. The most impor-
tant tumour marker for CRC is represented by the cell-
surface antigen, Carcinoembryonic Antigen (CEA), which is
encoded aswell asCEACAM3 (AdhesionMoleculeCEACor-
related) on chromosome 19. CEACAM3 is most specifically
expressed on the cell surface of CRC patients and therefore
its assessment in whole blood is considered a valuable index
of circulating CRC cell number [5].
In the perspective of investigating, as a further step,
potential correlation with the prognosis, the purpose of this
study is the use of the CEACAM3 blood expression, as index
of the amount of CTCs, to evaluate its trend at different times
in the perioperative course of CRC.
2. Materials and Methods
The study includes 38 patients (16 females and 22males), with
amean age of 71.0 years (range of 39–88) operated for CRC in
a single institution by the same surgeon (PB) from February
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2008 to July 2009 inclusively. Patients affected with cancers of
the extraperitoneal rectal portion were excluded. Additional
exclusion criteria were represented by metastatic disease
with the exception of nodal metastases, previous chemoradi-
otherapy, previous/synchronous neoplasms, and immunode-
ficiency. Right hemicolectomy included division of the ileo-
colic and right colic vessels on the superior mesenteric axis;
left hemicolectomy with anterior rectal resection included
division of inferior mesenteric artery at its origin after iden-
tification of the hypogastric nerve.
All the patients gave their written informed consent in
order to take part in the study. The study was approved by
the ethical committee of our hospital. In each patient, 10mL
samples of whole blood from the basilic vein at the elbow
articulation were collected each on the day before the opera-
tion, on the 1st and 5th postoperative day, and 6 months later.
In 20 patients, two additional samples of whole blood were
intraoperatively collected. The first was collected at the same
step of the operation (just before sectioning the vein) in all the
patients, in detail, from the vein draining the blood stream
from the tumor (inferior mesenteric vein and ileocolic vein
in neoplasms of the left colon/rectum and in neoplasms of
the ascending colon, resp.). The second of the intraoperative
samples was simultaneously taken from the basilic vein. Due
to technical problems, only 12 of the 20 pairs of intraoperative
samples could be successfully evaluated.Moreover, the results
of these samples were separately considered since they are
not comparable with the preoperative and postoperative ones
due to the very peculiar “experimental” conditions (such
as general anesthesia operative stress or different others) in
which they were obtained. All the whole blood samples in
EDTA were immediately stored at −80∘C and evaluated for
the expression of CEACAM3 bymeans of real-time PCR (RT-
PCR) in order to assess the number of CTCs.
Control values were obtained from ten patients affected
by colonic diverticular disease and comparable for age and
sex distribution with patients. The controls undergoing col-
onoscopy, at the same time, were negative and in each of them
a whole blood sample was collected and processed in exactly
the same way as the study group.
2.1. RNA Isolation. The whole blood was defrosted. One
volume of whole blood was resuspended in 1 volume of PBS
and in 2 volumes of Purification Lysis Solution (Applied Bios-
ystems, Foster City, CA). RNA was isolated using 6100
Nucleic Acid PrepStation (Applied Biosystems, Foster City,
CA), according to the manufacturer’s protocol, and then
stored at −80∘C.
The RNA concentration and purity were assessed spec-
trophotometrically by measuring their absorbance at 260 nm
and 280 nm. RNA fragmentation state was evaluated by 1.5%
agarose gel.
2.2. Real-Time Quantitative PCR. All RNA samples (200 ng)
were reverse transcribed to cDNA using iScript cDNA Syn-
thesis Kit (Biorad, Hercules, CA) according to the manufac-
turer’s protocol. Negative control without RNA was per-
formed.
TaqMan real-time quantitative PCRwas performed on an
ABI PRISM7000 SequenceDetector System (Applied Biosys-
tems, Foster City, CA). PCR products for CEA gene were
detected using gene-specific primers and probes labelledwith
reporter day FAM (Assay on Demand, Applied Biosystems,
Foster City, CA). GAPDH was used as endogenous control
gene for normalization and was detected using gene-specific
primers and probes labeled with reporter day VIC (Applied
Biosystems, Foster City, CA).
PCR reaction was carried out in triplicate on 96-well
plate with 20𝜇L per well using 1x TaqMan Universal PCR
MasterMix. After incubation for 2min at 50∘C and for 10min
at 95∘C, the reaction continues for 50 cycles at 95∘C for 15 sec
and at 60∘C for 1min.
At the end of the reaction, the results, expressed as dCt,
were evaluated using the ABI 7000 PRISM software and the
Ct values were exported to Microsoft Excel.
The mean of the expression values of CEACAM3 gene
obtained in controls was used as reference value to quantify
the relative expression of CEACAM3 levels in CRC patients.
2.3. Statistical Analysis. Values are reported as mean ± SD.
The assumption of normality for the distribution of the
primary endpoint was tested by means of a graphical check
and according to the Shapiro-Wilk test results. Comparisons
of average values of CEACAM3 expression level obtained
at surgery or in the postoperative phase with the baseline
one were performed with Student’s 𝑡-test for paired data.
Differences in the average values of CEACAM3 expression
level between different subgroups at each time in the study
were tested with ANOVA or ANCOVA when adjusting by
baseline value was required. The repeated measures analyses
were carried out using amixed linearmodel, assuming spatial
power structures of the covariance matrix. All reported 𝑝
values were two-sided. All analyses were performed by LB
and LT using SAS 9.2 (SAS Institute, Cary, North Carolina).
3. Results
A total of 228 blood samples were collected and examined for
the 38 patients enrolled in the study. Patient characteristics,
site of the neoplasm, and the type of the procedure performed
are given in Table 1.
3.1. Preoperative Findings. CEACAM3 dCt values in the
whole group ranged between 2.81 and 8.35 (mean 4.01 ±
2.42). The values did not differ on account of gender, site of
neoplasm, and clinical or pathological stage.
3.2. Findings in the First Postoperative Day. The values of the
whole group in the first postoperative day ranged between
−5.76 and 7.45 (mean 3.42 ± 2.69) with no significant dif-
ferences (𝑝 = 0.06) when compared with preoperative
findings. The values of the patients undergoing laparoscopic
procedures ranged between −5.76 and 7.02 (mean 2.86 ± 2.51)
and did not differ (𝑝 = 0.07) from those in the group operated
with laparotomic operation (range of 0.03–7.45, mean of 4.12
± 2.36).
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Table 1: Clinical/pathological characteristics of patients and associated CEACAM3 levels.
Time (days)
CEACAM3 levels
CEA values (Mean ± SD)
Mean ± SD Mean
95% CI
Median Range
All cases (𝑛 = 38)
0 4.01 ± 2.42 3.21 to 4.81 3.54 −2.81 to 8.36 4.95 ± 2.12
1 3.43 ± 2.69 2.54 to 4.31 3.02 −5.77 to 7.45 3.93 ± 2.63
5 3.46 ± 2.21 2.73 to 4.18 3.26 −0.95 to 7.39 4.20 ± 1.84
180 1.22 ± 1.62 0.69 to 1.76 1.19 −3.38 to 4.36 3.80 ± 2.32
Sex
Female (𝑛 = 16)
0 4.39 ± 2.34 3.14 to 5.64 4.21 1.53 to 8.36 4.98 ± 1.48
1 3.69 ± 2.54 2.33 to 5.04 3.42 0.03 to 7.21 3.69 ± 1.82
5 3.65 ± 2.37 2.39 to 4.91 2.56 0.89 to 7.14 3.65 ± 2.12
180 0.97 ± 1.87 −0.03 to 1.96 0.90 −3.38 to 4.36 3.50 ± 1.65
Male (𝑛 = 22)
0 3.74 ± 2.50 2.63 to 4.84 3.29 −2.81 to 8.03 4.28 ± 1.89
1 3.24 ± 2.84 1.98 to 4.50 3.02 −5.77 to 7.45 4.30 ± 2.74
5 3.31 ± 2.13 2.37 to 4.26 3.48 −0.95 to 7.39 3.90 ± 1.65
180 1.41 ± 1.43 0.77 to 2.04 1.25 −1.96 to 4.21 2.50 ± 1.43
Site
Caecum/ascending (𝑛 = 10)
0 3.13 ± 3.17 0.86 to 5.39 2.77 −2.81 to 8.03 4.37 ± 2.35
1 3.50 ± 2.73 1.54 to 5.45 3.16 −0.33 to 7.45 4.25 ± 1.89
5 2.94 ± 2.72 0.99 to 4.88 2.14 −0.95 to 7.39 4.50 ± 2.38
180 1.11 ± 1.35 0.15 to 2.08 0.83 −1.24 to 3.14 3.50 ± 2.62
Descending/sigmoid colon (𝑛 = 13)
0 5.06 ± 1.76 4.00 to 6.13 5.19 1.87 to 7.73 4.36 ± 1.72
1 3.78 ± 2.39 2.34 to 5.22 4.22 0.03 to 6.74 4.20 ± 1.69
5 4.01 ± 2.06 2.76 to 5.26 4.01 1.58 to 7.14 3.90 ± 2.15
180 1.16 ± 2.09 −0.10 to 2.42 1.20 −3.38 to 4.36 2.50 ± 1.62
Rectum (𝑛 = 15)
0 3.69 ± 2.17 2.49 to 4.89 2.59 1.24 to 8.36 5.09 ± 2.33
1 3.08 ± 3.03 1.40 to 4.76 2.89 −5.77 to 7.21 4.90 ± 2.63
5 3.32 ± 2.00 2.21 to 4.43 3.39 1.02 to 6.51 4.90 ± 1.56
180 1.35 ± 1.42 0.56 to 2.13 1.25 −1.96 to 4.21 3.50 ± 1.68
Stage pT
pT1-pT2 (𝑛 = 14)
0 3.37 ± 1.99 2.21 to 4.52 2.59 1.12 to 8.03 5.06 ± 2.78
1 2.36 ± 3.07 0.59 to 4.13 2.44 −5.77 to 7.45 4.96 ± 1.63
5 2.32 ± 1.86 1.24 to 3.39 1.64 0.89 to 7.39 4.70 ± 2.58
180 0.91 ± 1.45 0.07 to 1.75 1.01 −3.38 to 2.99 2.78 ± 1.13
pT3-pT4 (𝑛 = 24)
0 4.39 ± 2.61 3.29 to 5.49 4.88 −2.81 to 8.36 4.47 ± 2.27
1 4.05 ± 2.28 3.09 to 5.02 4.23 −0.33 to 7.21 4.25 ± 1.36
5 4.12 ± 2.16 3.21 to 5.03 4.11 −0.95 to 7.14 4.20 ± 2.62
180 1.40 ± 1.72 0.68 to 2.13 1.23 −1.96 to 4.36 3.98 ± 2.54
Pathological stage
I (𝑛 = 13)
0 3.51 ± 2.00 2.30 to 4.72 2.59 1.12 to 8.03 5.06 ± 3.03
1 2.48 ± 3.16 0.57 to 4.39 2.47 −5.77 to 7.45 4.70 ± 2.65
5 2.43 ± 1.89 1.28 to 3.57 1.69 1.02 to 7.39 4.67 ± 2.35
180 0.93 ± 1.51 0.02 to 1.84 1.01 −3.38 to 2.99 4.23 ± 1.89




CEA values (Mean ± SD)
Mean ± SD Mean
95% CI
Median Range
II (𝑛 = 12)
0 5.34 ± 2.01 4.06 to 6.62 5.32 2.31 to 8.36 4.58 ± 1.98
1 4.91 ± 1.94 3.68 to 6.15 5.17 0.58 to 7.21 4.90 ± 1.85
5 4.64 ± 1.72 3.54 to 5.73 4.90 1.84 to 6.51 4.62 ± 1.98
180 1.36 ± 1.45 0.44 to 2.28 1.29 −1.96 to 3.60 4.36 ± 2.62
III (𝑛 = 13)
0 3.29 ± 2.79 1.60 to 4.97 2.99 −2.81 to 7.73 2.66 ± 2.72
1 3.01 ± 2.35 1.59 to 4.42 2.94 −0.33 to 6.74 2.98 ± 2.65
5 3.40 ± 2.50 1.89 to 4.91 3.56 −0.95 to 7.14 2.48 ± 1.13
180 1.39 ± 1.95 0.21 to 2.56 0.89 −1.78 to 4.36 2.60 ± 1.64
3.3. Findings in the Fifth Postoperative Day. The values in the
whole group ranged between −0.94 and 7.38 (mean 3.45 ±
2.21): differences were significant when compared to pre-
operative samples (𝑝 = 0.01). The values of the patients
undergoing laparoscopic procedures did not significantly
differ from those in the laparotomy group.
3.4. Findings 6 Months after Operation. Values ranged
between −3.38 and 4.35 (mean 1.22 ± 1.62): differences were
significant when compared to preoperative samples; 𝑝 <
0.0001.
3.5. Intraoperative Findings. Values in the whole blood sam-
ples from basilic vein ranged between −0.93 and 5.23 (mean
1.89 ± 1.88), whereas in the samples which were simultane-
ously collected from the inferior mesenteric or ileocolic vein
they ranged between −1.26 and 4.76 (mean 2.33 ± 1.78) with
no significant differences. Intraoperative basilic vein samples
were significantly higher (𝑝 = 0.05) than the corresponding
preoperative ones. No differences were found between the
“laparoscopic” and the “laparotomic” group.
3.6. Time Evolution of CEACAM3 dCt. Overall, CEACAM3
duct values showed a decreasing trend from preoperative
through early and later postoperative to 6th-month samples
(𝑝 < 0.001; Figure 1). The same trend was observed when
the enrolled patients are stratified into two groups according
to the pT stage (T1/T2 and T3/T4) (𝑝 < 0.01). Moreover, the
average values of CEACAM3 duct of each perioperative set of
samples (time points: 0, 1, and 6) were related to the parietal
cancer invasion (𝑝 = 0.034, Figure 2). Meanwhile, as regards
the final samples (6months), we have observed that the values
of CEACAM3 similarly decreased in both groups of patients
regardless of T stage.
Similar data have been observed stratifying the patients
by WHO stage (𝑝 = 0.035, Figure 3). No evidence of any
relationship between the lymph node status and CEACAM3
dCt values was found (𝑝 = 0.621) at any time of the study.















Figure 1: Decreasing trend of overall CEACAM3 values from pre-
operative through early and later postoperative to 6th-month blood
samples.
Time (days) Time (days)
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Figure 2: Decreasing trend of CEACAM3 from perioperative to
early and late postoperative blood samples according to the pT
staging.
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Figure 3: Decreasing trend of CEACAM3 from perioperative to
early and late postoperative blood samples according to pathological
stage (WHO).
However, a significant effect of the baseline value of
CEACAM3 dCt on the temporal trend has been observed
(𝑝 < 0.001): a lower baseline value corresponds to a higher
decrease in the 6th-month sample. Moreover, the effect of
staging disappeared in the linear models adjusting by that
variable (𝑝 = 0.075 and 𝑝 = 0.243 for T stage and WHO
stage, resp.).
Finally, to evaluate if the use of CEACAM3 as marker
of CTCs is a good strategy, in the same patients, we have
compared the values of CEACAM3with blood CEA level, the
most popular marker of CRC. We have observed that in both
two categories (pT1-pT2 and pT3-pT4) of patients the trend
of CEACAM3 is similar to that of CEA, although the average
CEACAM3 values in the various time points are lower than
those of CEA, suggesting a greater specificity in identifying
the CTCs (Figure 4(a)). Finally, we have obtained similar data
comparing the blood values of CEACAM3 and CEA in the
patients grouped by the pathologic cancer stage (Figure 4(b)).
Also, in this case, the values of CEACAM3 were lower than
those of CEA, in particular that relating to the last blood
sampling (180 days).This is very important because the value
of the CEA also indicates the free antigen not bound to CTCs;
on the contrary, the value of CEACAM3 essentially refers to
the one linked to the CTCs and, so, is more specific marker
of the CTCs.
4. Discussion
The novelty of this study is represented by the postoperative
decreasing trend of CTCs in CRC patients. This can be
considered an expected finding; however, to our knowledge,
it has been demonstrated for the first time by the present
paper. The CTCs are involved in the hematogenous route
of metastasis and have been considered relevant for the
clinical outcome of malignancies such as breast, colorectal,
esophageal, and gastric cancers [6, 7]. The current definition
of the “seed and soil” hypothesis is founded upon three
principles. In the first place, neoplasms contain genetically
diverse tumor cell subsets, each with different metastatic
potential. Secondly, metastases are formed by those cells,
which succeed in completing all steps of the metastatic proc-
ess. Finally, the specific choice of “soil” is mostly deter-
mined by interactions between the tumor cell and the organ
microenvironment. These interactions may include tumor
cell specific recognition of endothelial cell antigens and
response to local growth factors [8].
Since metastatic disease seems to be the most important
cause of postoperative cancer-related death, detection and
evaluation of CTCs could provide a deep insight in the solid
neoplasm prognosis, which can be hardly foreseen on the
basis of the pathological/clinical stage only. As a matter of
fact, although CTCs represent a necessary (but not sufficient)
condition for distant metastasis, the presence/absence and
the number of CTCs may represent an important prognostic
factor.
After its introduction almost 15 years ago, RT-PCR is
now emerging as the most commonly used technique for the
detection of CTCs [9]. The main advantage of this approach
is its higher sensitivity when compared with that of other
currently available methods, which utilize RNA isolation
after enrichment of CTCs from whole blood [10]. To our
knowledge, RT-PCR is now considered the most sensitive
assay to detect tumor-specific molecular markers. Moreover,
its specificity is also very high as primers are designed for
the particular gene of interest and the whole genomic DNA
or RNA can be analyzed in one single reaction. In the detec-
tion/evaluation of CTCs from peripheral blood of cancer
patients, RT-PCR has been proposed for several genes such
as CEA, PTEN, and P27 [11].
Real-time quantitative PCR of CEA mRNA methods has
been previously considered reliable for this purpose [12], but
CEACAM3 mRNA seems to provide, despite being at the
moment insufficiently studied, the additional advantage of a
greater specificity in CRC [13]. Previous data suggest that, in
spite of a high sensitivity, a lack of specificity may condition
the efficiency of CEA mRNA expression in detecting CTCs
[14]. As a matter of fact, other causes may affect CEAmRNA:
among them, the upregulation of stem cells in peripheral
blood or the shedding of nonmalignant epithelial cells has
been reported [15]. For this is the reason, in this study,we have
used a more specific marker for CRCs such as CEACAM3.
The clinical interest in detection of CTCs is determined
by its possible correlation with the prognosis. However, the
purpose of the present paper is preliminary to the evaluation
of the impact of CTCs on prognosis and consists of the
assessment of their perioperative trend. In our study, no
differences were shown between preoperative and early post-
operative findings aswell as within the intraoperative samples
between portal and systemic blood. These data are in agree-
ment with those previously reported and obtained with the
same method and stand for a nonsignificant effect of surgical
manipulation on the cancer cell shedding [16]. Moreover,
they suggest that previous findings of increased postoperative
levels obtained with less specific PCR methods [17] might be
generically due to the shedding overall epithelial cell due to
surgical trauma.
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Figure 4: Comparison of CEACAM3 and CEA blood values in the CRC patients grouped by pT staging (a) or pathological stage (b).
The fourfold increase in CTCs of the study group before
the operation, when compared to controls, seems worthwhile
to notice. This data is in agreement with previous reports
in CRC, despite being obtained with different PCR methods
[18]. The persistence of high values of CEACAM3 dCT up
to the 5th postoperative day stands for a long life span for
tumoral cells, which significantly decrease to almost normal
values only in between the 5th postoperative day and the
6th month after the operation. Correspondence between the
portal and systemic CEACAM3 levels suggests an aspecific
filtration by the hepatic parenchyma and supports systemic
levels as a representative index of the real spontaneous
neoplastic cell shedding from the tumor.
5. Conclusions
Although the present data appear interesting, molecular
and/or morphologic characterization of CTCs seem to be
as important as their quantification and isolation. Therefore,
possible future developments of the study will be represented
by the investigation of the relationships of the different
methods [19] and more specifically by the association of the
present methodology with other methods of detection of
CTCs such as cell search, which may allow characterization
of CTCs and possibly a more accurate prognostic insight.
In spite of some limitations, the present study confirmed
the specificity of CEACAM3 as marker of CCTs and showed,
for the first time, a perioperative trend of CTCs which is
coherent with what could be expected on the basis of clinical
considerations and previous experimental findings which
have been reported for both CRC and other neoplasms.
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